Company CureVac N.V. Deutsche Boerse AG

Equities

5CV

NL0015436031

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for CureVac N.V.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 05:56:35 17/06/2024 pm IST			5-day change	1st Jan Change
3.367 ^EUR	-1.09%		-20.29%	-12.81%

28/05	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT
28/05	CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	CI

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Number of employees: 1,086

USD in Million	2022	Weight	2023	Weight	Delta
Transformative Medicines Based on Messenger Ribonucleic Acid 100.0 %	71	100.0 %	58	100.0 %	-17.98%

USD in Million	2022	Weight	2023	Weight	Delta
Belgium 87.7 %	65	92.4 %	51	87.7 %	-22.14%
Switzerland 10.1 %	4	5.0 %	6	10.1 %	+65.60%
Netherlands 2.2 %	2	2.7 %	1	2.2 %	-31.10%
Others 0.0 %	-	-	0	0.0 %	-

Managers	Title	Age	Since
Alexander Zehnder CEO	Chief Executive Officer	54	28/23/28
Pierre Kemula DFI	Director of Finance/CFO	50	01/16/01
Malte Greune COO	Chief Operating Officer	59	01/21/01
Sarah Fakih IRC	Investor Relations Contact	-	-
Myriam Mendila PRN	Corporate Officer/Principal	58	01/23/01

Members of the board	Title	Age	Since
Craig Tooman BRD	Director/Board Member	58	01/19/01
Michael Brosnan BRD	Director/Board Member	69	19/23/19
Klaus Schollmeier BRD	Director/Board Member	67	22/22/22
Baron Jean Stéphenne CHM	Chairman	73	01/15/01
Mathias Hothum BRD	Director/Board Member	58	01/15/01
Debra Stephanie Barker BRD	Director/Board Member	61	22/22/22
Viola Bronsema BRD	Director/Board Member	61	01/20/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	224,305,680	122,763,011 ( 54.73 %)	0	54.73 %

Name	Equities	%	Valuation
dievini Hopp BioTech holding GmbH & Co. KG 31.29 %	70,181,760	31.29 %	273 M €
Government of Germany 13.32 %	29,871,441	13.32 %	116 M €
GSK PLC 7.397 %	16,591,937	7.397 %	65 M €
Dietmar Hopp 4.589 %	10,294,503	4.589 %	40 M €
Zweite DH Verwaltungs GmbH 1.518 %	3,404,672	1.518 %	13 M €
Millennium Management LLC 1.231 %	2,761,090	1.231 %	11 M €
RA Capital Management LP 0.8764 %	1,965,707	0.8764 %	8 M €
BlackRock Advisors LLC 0.8168 %	1,832,082	0.8168 %	7 M €
Camber Capital Management LP 0.7802 %	1,750,000	0.7802 %	7 M €
Bill & Melinda Gates Foundation 0.7123 %	1,597,637	0.7123 %	6 M €

CureVac NV

Friedrich-Miescher-Strasse 15

72076, Tübingen

+49 7071 9883 0

http://www.curevac.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.431 EUR

Average target price

8.728 EUR

Spread / Average Target

+154.38%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+40.80%	5.37TCr
LONZA GROUP AG	+34.32%	3.89TCr
IQVIA HOLDINGS INC.	-8.05%	3.88TCr
CELLTRION, INC.	-8.98%	2.73TCr
ICON PUBLIC LIMITED COMPANY	+10.69%	2.59TCr
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	2.03TCr
UNITED THERAPEUTICS CORPORATION	+31.00%	1.28TCr
MEDPACE HOLDINGS, INC.	+28.51%	1.22TCr
BIO-TECHNE CORPORATION	-1.67%	1.2TCr

Other Biotechnology & Medical Research